Who We Are
Our History & Timeline
Contact us to discuss our flexible partnering and co-innovation options.
Founded in 2014
- Invented & owns the SELEX IP licensed to SomaLogic that provided rights to use modified nucleotides in SOMAmers
- Alliance partnerships with Novartis, Elanco, Editas Medicine, Janssen, Systems Oncology, and iCarbonX
- Multiple collaborations for in vitro selection of modification-enhanced RNA aptamers (High Performance Aptamers, "HPAs"), RNA construct engineering & synthesis
1st Aptamer Selections 1,2
Velocity Founder Bruce Eaton Invents Modified Nucleic Acid Aptamer Technology 3
Modified Aptamers Shown to Recognize Tripeptides Stereoselectively 4
Velocity’s modified aptamer technology enables highly multiplexed protein assays 5
Velocity Sciences Formed to solve challenges in biotechnology not addressable by antibodies or aptamers with unmodified nucleotides
Strategic Partnerships with Novartis, Lilly, Jansen, Editas and Others Have Enabled Velocity to Invent the Next Generation of Aptamer Technologies and refine its synthesis capabilities
Expanded Investment in RNA chemical and enzymatic synthesis and directed evolution capabilities to partner in the rapid growth of new oligonucleotide therapies
1. Tuerk, Gold, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505-510m, 1990.
2. Ellington, Szostak, In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822, 1990.
3. Dewey, Zyniewski, Eaton, The RNA World: Functional Diversity In A Nucleoside By Carboxyamidation OF Uridine, Nucleosides & Nucleotides, 15(10), 1611-1617, 1996.
4. Eaton, et al, The First Example of an RNA Urea Synthase: Selection through the Enzyme Active Site of Human Neutrophile Elastase, ChemBioChem, 4, 649-662, 2004.
5. Zichi, et al., Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery, PloS ONE, 5(12), e15004, 2010.